[go: up one dir, main page]

WO2024197798A1 - Composition pour le soin des matières kératiniques - Google Patents

Composition pour le soin des matières kératiniques Download PDF

Info

Publication number
WO2024197798A1
WO2024197798A1 PCT/CN2023/085408 CN2023085408W WO2024197798A1 WO 2024197798 A1 WO2024197798 A1 WO 2024197798A1 CN 2023085408 W CN2023085408 W CN 2023085408W WO 2024197798 A1 WO2024197798 A1 WO 2024197798A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
acid
magnesium
composition according
pca
Prior art date
Application number
PCT/CN2023/085408
Other languages
English (en)
Inventor
Zhiming Zhang
Yangdong CHEN
Hongling Xu
Xiaoming Huang
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Priority to PCT/CN2023/085408 priority Critical patent/WO2024197798A1/fr
Priority to FR2304785A priority patent/FR3147107A1/fr
Publication of WO2024197798A1 publication Critical patent/WO2024197798A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • Human skin is constituted of three compartments, namely a superficial compartment, which is the epidermis, the dermis and a deep compartment, which is the hypodermis.
  • the dermis is mainly constituted of fibroblasts and an extracellular matrix (ECM) .
  • ECM extracellular matrix
  • This extracellular matrix is constituted of various macromolecules responsible for the mechanical strength of the skin, its suppleness, its tonicity and its elasticity, and also for physiologically important functions (hydration, thermoregulation and regulation of the permeability of the skin) .
  • macromolecules include, in particular, collagens, elastin and glycoconjugates (glycoproteins and proteoglycans) .
  • Collagens represent 70%of the proteins of the ECM. Naturally, collagens are constantly renewed, but this renewal decreases with age, which leads to thinning of the dermis.
  • MMPI matrix metalloproteinase 1 or else interstitial collagenase
  • a wide variety of cosmetic products have been used to care for the skin, for example, to resist the ageing of the skin.
  • some cosmetic products do not deliver a good skin sensory after application.
  • An object of the present invention is thus to develop a composition for caring for the skin, which can effectively resist skin ageing and deliver a good skin sensory after application.
  • Another object of the present invention is to provide a cosmetic process for caring for the skin.
  • compositions for caring for the skin which can effectively resist skin ageing and deliver a good skin sensory after application.
  • the present invention provides a composition for caring for keratin materials comprising:
  • composition of the present invention can inhibit MMP-1 production, and effectively resist skin ageing.
  • composition of the present invention also can deliver a good smoothness and softness sensory.
  • the present invention provides a non-therapeutic method for caring for keratin materials, comprising applying the composition according to the first aspect of the present invention to the keratin materials.
  • Fig. 1 shows MMP-1 levels of different groups of cells in an in-vitro test.
  • keratin materials is intended to cover human skin, mucous membranes such as the lips. Facial skin is most particularly considered according to the present invention.
  • composition of the present invention comprises:
  • composition of the present invention comprises at least one Saccharomyces cerevisiae extract.
  • the Saccharomyces cerevisiae extract is an extract of the yeast cells of Saccharomyces cerevisiae.
  • the extract may exclude any other part or element of the yeast such as the wall or the membranes of the yeast.
  • the extract can be obtained by a process comprising the following steps: a. solubilization of at least 50 g/L of Saccharomyces cerevisiae in water, by mechanical homogenization, b. separation of the soluble and insoluble phases, c. ultrafiltration and filtrate recovery, and d. molecular sorting, in particular by membrane filtration.
  • the extract may comprise a protein fraction.
  • the distribution and quantity of the protein fraction can be determined by measuring total nitrogen according to the KJELDHAL method (reference: Official method of analysis of the A.O.C., 12th ed. W Horwitz, E.D., New-York, 15-60, 1975) .
  • the extract can be in liquid form or dry form.
  • the Saccharomyces cerevisiae extract is present in the composition of the present invention in an amount of dry matter ranging from 0.001 wt. %to 0.375 wt. %, preferably from 0.01 wt. %to 0.175 wt. %, more preferably from 0.05 wt. %to 0.1 wt. %, relative to the total weight of the composition.
  • Vitamin B3 and derivatives thereof
  • the composition of the present invention comprises at least one compound selected from vitamin B3 and derivatives thereof.
  • Vitamin B3 also called vitamin PP, is a compound of the following formula (A) :
  • R may be -CONH 2 (niacinamide) , -COOH (nicotinic acid or niacin) , or CH 2 OH (nicotinyl alcohol) , -CO-NH-CH 2 -COOH (nicotinuric acid) or -CO-NH-OH (niconityl hydroxamic acid) .
  • Vitamin B3 derivatives that may be mentioned include, for example, nicotinic acid esters such as tocopherol nicotinate, amides derived from niacinamide by substitution of the hydrogen groups of-CONH 2 , products from reaction with carboxylic acids and amino acids, esters of nicotinyl alcohol and of carboxylic acids such as acetic acid, salicyclic acid, glycolid acid or palmitic acid.
  • nicotinic acid esters such as tocopherol nicotinate
  • amides derived from niacinamide by substitution of the hydrogen groups of-CONH 2 products from reaction with carboxylic acids and amino acids
  • esters of nicotinyl alcohol and of carboxylic acids such as acetic acid, salicyclic acid, glycolid acid or palmitic acid.
  • vitamin B3 derivatives that may also be mentioned include its inorganic salts, such as chlorides, bromides, iodides or carbonates, and its organic salts, such as the salts obtained by reaction with carboxylic acids, such as acetate, salicylate, glycolate, lactate, malate, citrate, mandelate, tartrate, etc.
  • carboxylic acids such as acetate, salicylate, glycolate, lactate, malate, citrate, mandelate, tartrate, etc.
  • the compound selected from vitamin B3 and derivatives thereof is selected from niacinamide, nicotinic acid, nicotinyl alcohol, nicotinuric acid, niconityl hydroxamic acid, nicotinic acid esters, esters of nicotinyl alcohol and of carboxylic acids, 2-chloronicotinamide, 6- methylnicotinamide, 6-aminonicotinamide, N-methylnicotinamide, N, N-dimethylnicotinamide, N- (hydroxymethyl) nicotinamide, quinolinic acid imide, nicotinanilide, N-benzylnicotinamide, N-ethylnicotinamide, nifenazone, nicotinaldehyde, isonicotinic acid, methylisonicotinic acid, thionicotinamide, nialamide, 2-mercaptonicotinic acid, nicomol and
  • the compound selected from vitamin B3 and derivatives thereof is selected from niacinamide, nicotinic acid, nicotinyl alcohol, nicotinuric acid, niconityl hydroxamic acid, and combination thereof.
  • the composition of the present invention comprises niacinamide.
  • the compound selected from vitamin B3 and derivatives thereof is present in the composition of the present invention in an amount ranging from 0.01 wt. %to 7 wt. %, preferably from 0.1 wt. %to 5 wt. %, more preferably from 0.5 wt. %to 3 wt. %, relative to the total weight of the composition.
  • the composition of the present invention comprises at least one divalent metal salt.
  • the divalent metal salt comprises a metal ion M1 2+ .
  • M1 2+ is selected from Mg 2+ , Ca 2+ , Zn 2+ , and Cu 2+ .
  • the divalent metal salt is selected from metal salts of an organic acid or an inorganic acid.
  • organic acid mention can be made of ascorbic acid, formic acid, acetic acid, glycolic acid, gluconic acid, aspartic acid, lactic acid, mandelic acid, oxalic acid, maleic acid, malonic acid, glyoxylic acid, succinic acid, adipic acid, fumaric acid, sebacic acid, citric acid, tartaric acid, malic acid, tricarboxylic acid, glutaric acid, glucaric acid, pyrrolidone carboxylic acid, phenol sulfonic acid, salicylic acid, etc.
  • ascorbic acid formic acid, acetic acid, glycolic acid, gluconic acid, aspartic acid, lactic acid, mandelic acid, oxalic acid, maleic acid, malonic acid, glyoxylic acid, succinic acid, adipic acid, fumaric acid, sebacic acid, citric acid, tartaric acid, malic acid, tricarboxylic acid, glutaric acid
  • inorganic acid mention can be made of sulfuric acid, carbonic acid, silicic acid, hydrochloric acid, nitric acid, phosphoric acid, etc.
  • divalent metal salts of an inorganic acid are selected from metal chlorides, sulfates, nitrates, carbonates and hydrogen carbonates, phosphates, silicates, and mixtures thereof, wherein the metal is selected from Mg, Ca, Zn, and Cu.
  • divalent metal salts of an inorganic acid are selected from calcium chloride, calcium sulfate, calcium nitrate, calcium carbonate and hydrogen carbonate, calcium phosphate, zinc chloride, zinc sulfate, zinc nitrate, zinc carbonate and hydrogen carbonate, zinc phosphate, magnesium chloride, magnesium sulfate, magnesium nitrate, magnesium carbonate and hydrogen carbonate, magnesium phosphate, copper chloride, copper sulfate, copper nitrate, copper carbonate and hydrogen carbonate, copper phosphate, and mixtures thereof.
  • divalent metal salts of an organic acid are selected from metal ascorbates, formates, acetates, glycolates, aspartates, gluconates, lactates, mandelates, oxalates, maleates, malonates, glyoxylates, succinates, adipates, fumarates, sebacates, citrates, tartarates, malates, tricarboxylates, glutarates, glucarates, pyrrolidone carboxylates, phenolsulfonate, salicylates, and mixtures thereof, wherein the metal is selected from Mg, Ca, Zn, and Cu.
  • divalent metal salts of an organic acid are selected from magnesium gluconate, magnesium aspartate, magnesium PCA (Magnesium pyrrolidone carboxylate) , magnesium acetate, calcium PCA (calcium pyrrolidone carboxylate) , zinc lactate, zinc gluconate, zinc phenolsulfonate, zinc salicylate, zinc PCA (zinc pyrrolidone carboxylate) , zinc citrate, zinc ascorbate, zinc aspartate, copper PCA (copper pyrrolidone carboxylate) , copper gluconate, copper aspartate, and mixtures thereof.
  • magnesium PCA Magnnesium pyrrolidone carboxylate
  • magnesium acetate calcium PCA (calcium pyrrolidone carboxylate)
  • calcium PCA calcium pyrrolidone carboxylate
  • zinc lactate zinc lactate
  • zinc gluconate zinc phenolsulfonate
  • zinc salicylate zinc PCA (zinc pyrrolidone carboxylate
  • the divalent metal salt is selected from magnesium gluconate, magnesium aspartate, magnesium PCA, magnesium sulfate, magnesium acetate, magnesium carbonate, calcium carbonate, calcium PCA, calcium chloride, calcium carbonate, zinc PCA, zinc gluconate, copper PCA, copper gluconate, and a mixture thereof.
  • the divalent metal salt is present in the composition of the present invention in an amount ranging from 0.00001 wt. %to 1 wt. %, preferably from 0.00005 wt. %to 0.5 wt. %, more preferably from 0.0001 wt. %to 0.1 wt. %, relative to the total weight of the composition.
  • composition of the present invention comprises at least one at least one monosaccharide selected from mannose, glucose, galactose, fructose, and combinations thereof.
  • composition according to the present invention comprises mannose, i.e., the compound of the following formula:
  • composition according to the present invention comprises glucose, i.e., the compound of the following formula:
  • composition according to the present invention comprises galactose, i.e., the compound of the following formula:
  • composition according to the present invention comprises fructose, i.e., the compound of the following formula:
  • the composition comprises glucose.
  • the monosaccharide is present in the composition of the present invention in an amount ranging from 0.01 wt. %to 2 wt. %, preferably from 0.05 wt. %to 1.5 wt. %, more preferably from 0.1 wt. %to 1 wt. %, relative to the total weight of the composition.
  • composition of the present invention may comprise an aqueous phase.
  • Said aqueous phase comprises water.
  • water is present in the composition of the present invention in an amount ranging from 50 wt. %to 98 wt. %, preferably from 60 wt. %to 95 wt. %, more preferably from 70 wt. %to 93 wt. %, relative to the total weight of the composition.
  • the aqueous phase comprises an organic solvent miscible with water (at room temperature 25°C) selected from monoalcohols, glycols and polyols having from 2 to 20 carbon atoms, such as octyldodecanol, glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol, dipropylene glycol, diethylene glycol; and mixtures thereof, so as to provide a hydration effect.
  • an organic solvent miscible with water selected from monoalcohols, glycols and polyols having from 2 to 20 carbon atoms, such as octyldodecanol, glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol, dipropylene glycol, diethylene glycol; and mixtures thereof, so as to provide a hydration effect.
  • the organic solvent miscible with water selected from monoalcohols, glycols and polyols is present in the composition in an amount ranging from 0.5 wt. %to 20 wt. %, preferably from 1 wt. %to 10 wt. %, relative to the total weight of the composition.
  • the continuous aqueous phase of the composition of the present invention comprises water and glycerin.
  • composition of the present invention may comprise an oily phase.
  • the oily phase contains at least one oil, notably a cosmetic oil. It may also contain other fatty substances.
  • oil means a water-immiscible non-aqueous compound that is liquid at room temperature (20°C) and at atmospheric pressure (760 mmHg) .
  • the oils may be volatile or non-volatile.
  • non-volatile refers to an oil whose vapour pressure at room temperature and atmospheric pressure is non-zero and is less than 10-3 mmHg (0.13 Pa) .
  • volatile oil means any oil that is capable of evaporating on contact with the skin in less than one hour, at room temperature and atmospheric pressure.
  • the oily phase may comprise hydrocarbon-based oils, silicone oils, or mixtures thereof.
  • They may be of animal, plant, mineral or synthetic origin.
  • hydrocarbon-based oil means an oil mainly containing hydrogen and carbon atoms.
  • the oils may optionally comprise oxygen, nitrogen, sulfur and/or phosphorus atoms, for example in the form of hydroxyl or acid radicals.
  • composition of the present invention may comprise an additional cosmetic active ingredient in addition to the cosmetic active compound of formula (I) as defined previously.
  • moisturizing agents examples include moisturizing agents; vitamins such as vitamin A (retinol) , vitamin E (tocopherol) , vitamin C (ascorbic acid) , vitamin B5 (panthenol) , and derivatives of said vitamins (in particular esters) and mixtures thereof; brightening agents; tightening agents; peeling agents; moisturizing and hydration agents (HA) , repairing and soothing agents; other anti-aging agents; agents acting on the microcirculation, and mixtu res thereof.
  • vitamins such as vitamin A (retinol) , vitamin E (tocopherol) , vitamin C (ascorbic acid) , vitamin B5 (panthenol) , and derivatives of said vitamins (in particular esters) and mixtures thereof
  • brightening agents tightening agents
  • peeling agents moisturizing and hydration agents (HA) , repairing and soothing agents
  • other anti-aging agents agents acting on the microcirculation, and mixtu res thereof.
  • composition of the present invention may comprise may also contain conventional cosmetic adjuvants or additives, for instance fragrances, chelating agents, preserving agents and bactericides, surfactants, thickeners, pH regulators, and mixtures thereof.
  • conventional cosmetic adjuvants or additives for instance fragrances, chelating agents, preserving agents and bactericides, surfactants, thickeners, pH regulators, and mixtures thereof.
  • the present invention provides a composition for caring for keratin materials comprising, relative to the total weight of the composition:
  • At least one divalent metal salt is selected from magnesium gluconate, magnesium aspartate, magnesium PCA, magnesium acetate, magnesium carbonate, calcium carbonate, calcium PCA, calcium chloride, calcium carbonate, zinc PCA, zinc gluconate, copper PCA, copper gluconate, and a mixture thereof; and
  • composition of the present invention is in the form of emulsion, cream, lotion, or hydrogel.
  • composition of the present invention can be used for caring for keratin materials.
  • the present invention provides a non-therapeutic method for caring for keratin materials, comprising applying the composition according to the first aspect of the present invention to the keratin materials.
  • the present invention provides a non-therapeutic method for antiaging of keratin materials, comprising applying the composition according to the first aspect of the present invention to the keratin materials.
  • the keratin material is the skin.
  • compositions of invention example (IE) 1 and comparative examples (CE) 1-4 were prepared based on the amounts given in Table 2. The amounts are given in%by weight of active ingredient relative to the total weight of the composition.
  • Composition of invention example 1 represents composition according to the present invention.
  • Composition of comparative example 1 does not comprise a divalent metal salt.
  • Composition of comparative example 2 does not comprise Saccharomyces cerevisiae extract.
  • Composition of comparative example 3 does not comprise a compound selected from vitamin B3 and derivatives thereof.
  • Composition of comparative example 4 does not comprise a monosaccharide selected from mannose, glucose, galactose, fructose, and combination.
  • compositions listed above were prepared as follows:
  • phase A1 1) . introducing the components of phase A1 into a main container with mixing and heating to 80°C for 6 minutes;
  • phase A2 1) introducing the components of phase A2, the components of Phase A3 with mixing, phase by phase to obtain an uniform mixture;
  • phase B water
  • HDFs Human primary dermal fibroblasts
  • the first group was treated with 0.3 wt. % (based on the total weight of the culture medium) of composition of comparative example 1 for another 24 hours, then subjected to 10J UVA light, and lastly treated with 0.3 wt. %of composition of comparative example 1 for 48 hours.
  • the second group was treated with 0.3 wt. %of composition of invention example 1 for another 24 hours, then subjected to 10J UVA light, and lastly treated with 0.3 wt. %of composition of invention example 1 for 48 hours.
  • the third group (as positive control) was treated with 0.1uM dexamethasone (DT, as positive control) for another 24 hours, then the human primary dermal fibroblasts were subjected to 10J UVA light, and lastly treated with 0.1uM dexamethasone for 48 hours.
  • the fourth group (as blank control A) was cultured with normal culture medium (i.e., not treated with any composition or dexamethasone) for another 24 hours, not subjected to UVA light, and lastly cultured with normal culture medium for 48hours.
  • normal culture medium i.e., not treated with any composition or dexamethasone
  • the fifth group (as blank control B) was cultured with normal culture medium (i.e., not treated with any composition or dexamethasone) for another 24 hours, then subjected to UVA light, and lastly cultured with normal culture medium for 48hours.
  • normal culture medium i.e., not treated with any composition or dexamethasone
  • Table 3 shows grouping with different treatment conditions.
  • Fig. 1 shows MMP-1 levels of different groups of cells in an in-vitro test.
  • composition of inventive example 1 can reverse the MMP-1 release induced by UVA more significantly than composition of comparative example 1.
  • composition of invention example 1 delivers better softness sensory
  • four experts deem that there is no difference on softness sensory between the two compositions
  • one experts deems that composition of comparative example 1 is better than composition of invention example 1 in terms of softness sensory
  • six experts deem that composition of invention example 1 delivers better smoothness sensory
  • four experts deem that there is no difference on smoothness sensory between the two composition.
  • composition of invention example 1 delivers better softness sensory, and three experts deem that there is no difference on softness sensory between the two compositions, while all of 10 experts deem that composition of invention example 1 delivers better smoothness sensory.
  • composition of comparative example 3 As compared with composition of comparative example 3, seven experts deem that composition of invention example 1 delivers better softness sensory, and three experts deems that composition of comparative example 3 is better than composition of invention example 1 in terms of softness sensory, while five experts deem that composition of invention example 1 delivers better smoothness sensory, and five experts deem that composition of comparative example 3 is better than composition of invention example 1 in terms of smoothness sensory.
  • composition of comparative example 4 delivers better softness sensory and four experts deems that composition of comparative example 4 is better than composition of invention example 1 in terms of softness sensory, while five experts deem that composition of invention example 1 delivers better smoothness sensory and five experts deems that composition of comparative example 4 is better than composition of invention example 1 in terms of smoothness sensory.
  • composition of invention example 1 delivers significantly better softness and smoothness sensory than compositions of comparative examples 1 and 2, and significantly better softness sensory than composition of comparative example 3, sightly better softness sensory than compositions of comparative example 4.
  • composition according to the present invention can inhibit MMP-1 production, therefore can effectively resist skin ageing, meanwhile, it can deliver a deliver a good smoothness and softness sensory.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pour le soin des matières kératiniques comprenant : (i) au moins un extrait de Saccharomyces cerevisiae ; (ii) au moins un composé choisi parmi la vitamine B3 et ses dérivés ; (iii) au moins un sel métallique divalent ; et (iv) au moins un monosaccharide choisi parmi le mannose, le glucose, le galactose, le fructose, et des associations de ceux-ci. L'invention concerne également un procédé non thérapeutique pour le soin des matières kératiniques, comprenant l'application de ladite composition sur les matières kératiniques.
PCT/CN2023/085408 2023-03-31 2023-03-31 Composition pour le soin des matières kératiniques WO2024197798A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2023/085408 WO2024197798A1 (fr) 2023-03-31 2023-03-31 Composition pour le soin des matières kératiniques
FR2304785A FR3147107A1 (fr) 2023-03-31 2023-05-15 Composition de soin de matières kératineuses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2023/085408 WO2024197798A1 (fr) 2023-03-31 2023-03-31 Composition pour le soin des matières kératiniques

Publications (1)

Publication Number Publication Date
WO2024197798A1 true WO2024197798A1 (fr) 2024-10-03

Family

ID=92902749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/085408 WO2024197798A1 (fr) 2023-03-31 2023-03-31 Composition pour le soin des matières kératiniques

Country Status (2)

Country Link
FR (1) FR3147107A1 (fr)
WO (1) WO2024197798A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080159970A1 (en) * 2006-12-20 2008-07-03 L'oreal Kit comprising silicone compounds and a cosmetic and/or dermatological active agent
WO2012072951A1 (fr) * 2010-12-02 2012-06-07 L'oreal Utilisation d'extrait de levure du genre saccharomycespour améliorer l'éclat du teint et composition comprenant au moins cet extrait et un agent dépigmentant
CN103153321A (zh) * 2010-09-30 2013-06-12 Elc管理公司 含有吡咯烷酮羧酸锌(zinc pca)和榆绿木(anogeissus)提取物的组合物
CN105640870A (zh) * 2016-03-02 2016-06-08 名臣健康用品股份有限公司 一种含酵母提取物的皮肤护理组合物及皮肤护理产品
CN108882951A (zh) * 2016-02-12 2018-11-23 罗丹菲尔茨有限责任公司 保湿组合物及其用途
CN110917054A (zh) * 2019-12-11 2020-03-27 广州皇伽生物科技有限公司 一种护肤品用美白祛斑组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101015570A (zh) * 2007-03-08 2007-08-15 杜灵广 益生菌儿童保健食品及其生产工艺
JP5758175B2 (ja) * 2011-03-31 2015-08-05 株式会社ナリス化粧品 抗酸化剤、及び抗酸化化粧料
WO2018236069A1 (fr) * 2017-06-21 2018-12-27 코오롱인더스트리 주식회사 Composition cosmétique respectueuse de l'environnement pour l'hydratation et l'amélioration de l'élasticité de la peau
EP3744339B1 (fr) * 2019-05-28 2021-12-22 Chanel Parfums Beauté Extrait fermente de parties aeriennes de neroli

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080159970A1 (en) * 2006-12-20 2008-07-03 L'oreal Kit comprising silicone compounds and a cosmetic and/or dermatological active agent
CN103153321A (zh) * 2010-09-30 2013-06-12 Elc管理公司 含有吡咯烷酮羧酸锌(zinc pca)和榆绿木(anogeissus)提取物的组合物
WO2012072951A1 (fr) * 2010-12-02 2012-06-07 L'oreal Utilisation d'extrait de levure du genre saccharomycespour améliorer l'éclat du teint et composition comprenant au moins cet extrait et un agent dépigmentant
CN108882951A (zh) * 2016-02-12 2018-11-23 罗丹菲尔茨有限责任公司 保湿组合物及其用途
CN105640870A (zh) * 2016-03-02 2016-06-08 名臣健康用品股份有限公司 一种含酵母提取物的皮肤护理组合物及皮肤护理产品
CN110917054A (zh) * 2019-12-11 2020-03-27 广州皇伽生物科技有限公司 一种护肤品用美白祛斑组合物

Also Published As

Publication number Publication date
FR3147107A1 (fr) 2024-10-04

Similar Documents

Publication Publication Date Title
JP5038331B2 (ja) 銅と亜鉛の組成物を用いた老化防止治療
CN104856892B (zh) 一种富含生长因子的化妆品或护肤品制剂及其制备方法
JP7489687B2 (ja) 毛髪の成長と毛髪の固定を促進するための、無細胞脂肪組織抽出物を含有する組成物
CN107440955A (zh) 一种抗敏修护面霜
KR20160064410A (ko) 스피큘을 포함하는 피부관리용 화장품 조성물 및 이의 제조방법
US20180360712A1 (en) Cosmetic composition and use thereof
US20190298688A1 (en) Putrescine slow-release topical formulations
JP2017114814A (ja) 化粧料
CN113499281A (zh) 一种稳定悬浮体系及其制备方法和化妆品
KR20180134468A (ko) 스피큘과 해양콜라겐 및 해양심층수를 포함하는 해양 화장품 조성물 및 이의 제조방법
JP2018021029A (ja) 保湿力に優れた皮膚角質除去用化粧料組成物
RU2591789C1 (ru) Косметическая композиция для ухода за кожей лица и шеи
US8377434B2 (en) Cosmetic composition for exfoliating skin keratin
JP5329830B2 (ja) Ｓｃｆ分泌抑制剤、及び皮脂分泌抑制剤
JP2013209302A (ja) リンゴ幼果抽出物を含む表皮幹細胞性維持剤
WO2024197798A1 (fr) Composition pour le soin des matières kératiniques
KR102744422B1 (ko) 카르니틴살리실레이트(ca-sa)를 유효성분으로 포함하는 화장료 조성물
CN105287282B (zh) 一种巧克力泥营养面膜及其制备方法
JP2005343882A (ja) ヒアルロン酸産生促進剤、アクアポリン合成促進剤、及び皮膚外用剤組成物
KR20170038581A (ko) Aha, 우레아, 및 니아신아마이드를 포함하는 각질 연화용 및 미백용 화장료 조성물
JPH101414A (ja) 皮膚化粧料
CN104287982B (zh) 一种调节头皮油脂平衡的去屑组合物
JPH101410A (ja) 皮膚化粧料
JP2016525128A (ja) 皮膚を環境ストレッサーから防御する方法
WO2004022024A1 (fr) Compositions comprenant des produits au soja et des sels organiques de certains metaux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23929384

Country of ref document: EP

Kind code of ref document: A1